Indonesia, researchers revealed that this gene mutation causes increased levels of a chemical in the brain that can trigger the emergence of a tumor or cancer. 
With the discovery of a gene mutation that triggers key to the emergence of a tumor, then this may cause expectations to inhibit the production of these chemicals in order to prevent the emergence of a malignant tumor.
People who have certain brain tumors such as gliomas low levels, usually due to the mutation of genes can control the production of an enzyme called IDH1. Recent studies show these mutations alter the workings of an enzyme that can enhance the chemical 2-hidroksiglutarat (2HG) in the brain.
Researchers found samples malignant glioma patients with IDH1 mutations had 100 times more material than 2HG samples from patients who did not have mutations. By measuring levels of 2HG can be used to help identify patients with brain tumors due to IDH1 mutations.
"In addition, patients with low levels of gliomas may benefit from therapeutic inhibition of the production 2HG, this inhibition could be possible to slow or inhibit the low level of gliomas become secondary glioblastoma multiforme are more dangerous," said Professor Lew Cantley, a surgeon at Beth Israel Deaconess Medical Center , as quoted by BBC News, Monday (23/11/2009).
Cantley and his team use a specific area for research, called the metabolism of cancer, these techniques focus to study how changes in metabolic activity of cancer cells. "What was previously inactive, in fact, this enzyme oncogenes (genes that modified so that the increased tumor cell malignancy) is active and could be a potential therapeutic target," says Cantley.
Dr Laura Bell, of the charity Cancer Research UK reveal the results of this study provide interesting new information about how the brain tumor can grow and how to slow him down so you can help your doctor determine what is appropriate treatment for cure.
Hopefully with this information can help researchers to determine the appropriate therapy for patients with brain cancer later in order to survive and to cure illness.
With the discovery of a gene mutation that triggers key to the emergence of a tumor, then this may cause expectations to inhibit the production of these chemicals in order to prevent the emergence of a malignant tumor.People who have certain brain tumors such as gliomas low levels, usually due to the mutation of genes can control the production of an enzyme called IDH1. Recent studies show these mutations alter the workings of an enzyme that can enhance the chemical 2-hidroksiglutarat (2HG) in the brain.
Researchers found samples malignant glioma patients with IDH1 mutations had 100 times more material than 2HG samples from patients who did not have mutations. By measuring levels of 2HG can be used to help identify patients with brain tumors due to IDH1 mutations.
"In addition, patients with low levels of gliomas may benefit from therapeutic inhibition of the production 2HG, this inhibition could be possible to slow or inhibit the low level of gliomas become secondary glioblastoma multiforme are more dangerous," said Professor Lew Cantley, a surgeon at Beth Israel Deaconess Medical Center , as quoted by BBC News, Monday (23/11/2009).
Cantley and his team use a specific area for research, called the metabolism of cancer, these techniques focus to study how changes in metabolic activity of cancer cells. "What was previously inactive, in fact, this enzyme oncogenes (genes that modified so that the increased tumor cell malignancy) is active and could be a potential therapeutic target," says Cantley.
Dr Laura Bell, of the charity Cancer Research UK reveal the results of this study provide interesting new information about how the brain tumor can grow and how to slow him down so you can help your doctor determine what is appropriate treatment for cure.
Hopefully with this information can help researchers to determine the appropriate therapy for patients with brain cancer later in order to survive and to cure illness.
Tidak ada komentar:
Posting Komentar